You are here
Glycobia, Inc.
UEI: JNVRYXCFG2G3
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Novel strategy to generate glycan-specific antibodies for cancer immunotherapy
Amount: $300,000.00PROJECT SUMMARY ABSTRACT Almost half of all men and women in the United States will be diagnosed with cancer during their lifetimesresulting in more thandeaths and an economic burden exceeding $billio ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
N glycan specific antibodies for advancing glycobiology research
Amount: $150,000.00Project Summary Carbohydrate chains known as glycans are fundamental to a wide spectrum of biological processes including anticoagulation cell growth and development cell cell communication immu ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
IGF OT IGF TOPIC CHEMICALLY DEFINED GLYCAN LIBRARIES FOR REFERENCE STANDARDS AND GLYCOMICS RESEARCH JOINT NCI NIGMS PROGRAM
Amount: $999,898.00Not Available
SBIRPhase II2015Department of Health and Human Services National Institutes of Health -
Glycoconjugate therapeutic peptides for improved treatment of human diseases
Amount: $1,403,380.00DESCRIPTION provided by applicant Therapeutic peptides are used to treat human diseases ranging from HIV to diabetes and have some of the best features of small molecule and recombinant protein dru ...
SBIRPhase II2015Department of Health and Human Services National Institutes of Health -
Engineering Escherichia coli for sialylation of therapeutic proteins
Amount: $1,197,523.00DESCRIPTION provided by applicant Glycoengineering is a clinically validated strategy to enhance the therapeutic properties of protein and peptide drugs This strategy involves the attachment and m ...
SBIRPhase II2014Department of Health and Human Services National Institutes of Health -
Multiplexed Protein and miRNA Biomarker-based Next-gen Test for Alzheimers Disease
Amount: $197,758.00DESCRIPTION: Therapeutic peptides are used to treat human diseases ranging from HIV to diabetes and have some of the best features of small molecule and recombinant protein drugs. Therapeutic peptide ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health -
BOTTOM-UP GLYCOENGINEERING LIBRARY OF N-GLYCANS
Amount: $299,450.00Glycans are directly involved in the pathology of many major diseases. Glycosylated biomolecules are involved in biological functions including cell signaling, cell growth, immunity, three-dimensiona ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health -
Production of recombinant human glucocerebrosidase in Escherichia coli
Amount: $175,860.00DESCRIPTION (provided by applicant): Gaucher's disease is the most common lysosomal storage disease in humans resulting in the harmful accumulation of fatty glucocerebroside in the spleen, liver, ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
Engineering Escherichia coli for glycosylation of complex human proteins
Amount: $1,608,039.00DESCRIPTION (provided by applicant): Escherichia coli was the host organism for production of the first approved recombinant protein therapeutic in 1982. We now know that most therapeutic proteins req ...
SBIRPhase II2011Department of Health and Human Services National Institutes of Health -
Therapeutic antibody fragments from glycoengineered Escherichia coli
Amount: $391,734.00DESCRIPTION (provided by applicant): Omalizumab (XolairTM) is a recombinant monoclonal anti-IgE antibody used in the fight against severe allergic asthma that generates 500 million per year. However, ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health